SCHEMBL30280398

SCHEMBL30280398

Cc1ccc(S(=O)(=O)n2c(C=O)cc3cc(Br)cnc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 3/20 0.47
ENPP1 P22413 2/20 0.47
TP53 P04637 1/20 0.39
ALDH3A1 P30838 2/20 0.38
GAA P10253 2/20 0.36
LMNA P02545 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
NOD1 Q9Y239 2/20 0.36
CXCL8 P10145 1/20 0.36
NOD2 Q9HC29 1/20 0.36
ABL1 P00519 1/20 0.36
BCR P11274 1/20 0.36
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTT P42858 2/20 0.35
POLB P06746 1/20 0.35
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30280410 1.00 ENPP3 (0.47) ENPP3ENPP1TP53ALDH3A1GAA
SCHEMBL29606592 0.86 ENPP3 (0.54) ENPP3ENPP1TP53ALDH3A1GAA
SCHEMBL30280392 0.82 ENPP3 (0.48) ENPP3ENPP1TP53ALDH3A1GAA
SCHEMBL1778896 0.80 L3MBTL1 (0.55) ENPP3ALDH3A1GAALMNAL3MBTL1
SCHEMBL30280426 0.80 ENPP3 (0.46) ENPP3ENPP1TP53ALDH3A1GAA
SCHEMBL20502417 0.80 ENPP3 (0.48) ENPP3ENPP1TP53ALDH3A1GAA
SCHEMBL2962005 0.79 GAA (0.48) ENPP3ENPP1TP53GAALMNA
SCHEMBL25403944 0.76 ENPP3 (0.43) ENPP3ENPP1TP53ALDH3A1GAA
SCHEMBL30280386 0.76 ENPP3 (0.45) ENPP3ENPP1TP53ALDH3A1GAA
SCHEMBL21470743 0.76 PTGDR2 (0.42) TP53ALDH3A1GAALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 US disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH ENPP3 1096/4885ENPP1 1738/4885TP53 3015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.